To determine the clinical and economic impact attributable to upper gastrointestinal bleeding (UGIB) acquired in a pediatric intensive care unit (PICU). Prospective case-control-within-cohort study. PICU at a university hospital. All consecutive patients over a 1-yr period. All UGIB (hematemesis or blood in gastric tube) were reported. A UGIB was qualified as clinically significant (CS-UGIB) if a panel of reviewers assessed that a complication (decreased hemoglobin concentration, transfusion, multiple organ dysfunction syndrome, surgery, or death) was attributed to it. A UGIB was qualified as clinically nonsignificant (NS-UGIB) if none of these complications was attributed to it. The Ø-UGIB group comprised patients without UGIB. Pairing between the three groups was done according to these criteria: death or survival, Pediatric Risk of Mortality Score on admission, respiratory failure, coagulopathy, and age. Data considered for the impact analysis was prospectively monitored during the stay in PICU. Costs were estimated in Canadian dollars (1999) as follows: costs of stay + medical staff + ventilation + red blood cell transfusions. The cohort included 1006 admissions. Sixteen cases of CS-UGIB were paired to 13 cases of NS-UGIB and 32 cases of Ø-UGIB. Compared with the Ø-UGIB group and the NS-UGIB group, the CS-UGIB group showed a significantly (p < 0.05) higher rate of red blood cell transfusions, duration of ventilation, length of stay in PICU, and a lower hemoglobin level. There was no difference between the NS-UGIB group and the Ø-UGIB group. The cost analysis demonstrated a significant difference (p < 0.05) between the CS-UGIB group (20,062.67 Can dollars/patient per stay) and the other groups (NS-UGIB, 6104.77 Can dollars/patient per stay; Ø-UGIB, 5457.25 Can dollars/patient per stay). This study demonstrates a significant clinical and economic impact of CS-UGIB in PICU, although no impact was detected for NS-UGIB. Further studies on the benefit of UGIB prophylaxis for critically ill children with risk factors for CS-UGIB are needed.
The aim of this study was to evaluate both the errors and completeness of orders for intravenous medications and fluids in the resuscitation/trauma room of a pediatric emergency department before and after implementation of a standard order form. After implementing a standard order form in March 2004, a retrospective chart review of patients admitted to the resuscitation/trauma room of a pediatric tertiary care hospital in March, May, and July 2003 and, again in the same months 1 year later, in 2004. The completeness criteria were based on recommendations from the Institute for Safe Medication Practice and are the same as the ones used in our hospital. Medication errors and their severity were classified according to definitions of the American Society of Health-System Pharmacists. In the 3 months studied in 2003, 14 (5%) of 276 written orders fit the standard of completeness, whereas in the 3 months studied in 2004, 93 (33%) of 281 were complete. There were 55 (15%) medication errors of 372 orders in 2003 and 20 (6%) of 347 orders in 2004. Thus, during the 2 study periods, there was an increase in completeness (Δ 28%; 95% confidence interval, 22%-34%) and a decrease in medication errors (Δ 9%; 95% confidence interval, 5%-13%). Most of the errors had no adverse effects on patients. However, 11 errors (10 in 2003 and 1 in 2004) required some intervention. Most interventions resulted in the need for an additional dose of medication because of underdosage. A standard designated order form was associated with an increase in completeness and with a decrease in prescribing errors in the resuscitation/trauma room of a pediatric emergency department.
12 December 2011 in Journal of Evaluation in Clinical Practice